Thiomersal: implementation of the warning statement relating to sensitisation

  • Email
  • Help
Current version

Position paper

Reference numberEMEA/CHMP/VWP/19541/2007
KeywordsThiomersal, preservative, vaccines, immunoglobulins, antimicrobial, organomercuric, summary of product characteristics (SmPC), sensitisation

This document provides guidance on the wording of the summary of product characterisitics and the package lefleat for the use of thiomersal in medicinal products with regard to sensitisation.


A 2016 review of this guideline concluded that it remains up-to-date and relevant.


How helpful is this page?

Average rating:

 Based on 35 ratings

Add your rating:

See all ratings
7 ratings
7 ratings
7 ratings
7 ratings
7 ratings

Tell us more